Navigation Links
Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
Date:2/5/2008

SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today announced that David Ramsay, Halozyme's Vice President and Chief Financial Officer, will present at two investor conferences in February. Mr. Ramsay will present an overview of the Company and its product candidates and 2008 milestones at each conference.

-- 10th Annual BIO CEO & Investor Conference at The Waldorf-Astoria Hotel

in New York, NY on Tuesday, February 12, 2008 at 2:00 p.m. Eastern

Time (11:00 a.m. Pacific Time); and

-- Roth 20th Annual Growth Stock Conference to be held at the Ritz

Carlton Hotel in Laguna Niguel, CA on Thursday, February 21, 2008 at

11:00 a.m. Pacific Time (2:00 p.m. Eastern Time).

Interested parties can access a live audio webcast and accompanying slides of the conference presentations via the Internet by visiting the Investor Relations section of the Company's website at http://www.halozyme.com. Archived presentations will be available on the website for 30 days following the presentation date.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products based on the extracellular matrix for the drug delivery, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

Halozyme Contact

David A. Ramsay

Chief Financial Officer

(858) 704-8260


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... Orthogonal, ... on their recent FDA Class II 510(k) clearance for their flagship medical device, ... commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. While other companies ...
(Date:12/2/2016)... 2016 The immunohistochemistry (IHC) market is ... CAGR of 7.3% during the forecast period of 2016 to 2021 ... segment accounted for the largest share of immunohistochemistry (IHC) market, by ... , , ... (IHC) market spread across 225 pages, profiling 10 companies and supported ...
(Date:11/30/2016)... New York , November 30, 2016 ... consolidated as a few players hold a dominant share ... Group, Charles River Laboratories International, Inc., and Merck KGaA, ... market in 2015. Transparency Market Research observes that these ... are focused on development products that are do not ...
(Date:11/30/2016)... Nov. 30, 2016 /PRNewswire/ -  Equicare Health Inc ., ... been recognized as one of the top 100 companies ... international listing that distinguishes the top digital health companies ... great step forward this year continually upgrading our product ... customer base and team," says Len Grenier , ...
Breaking Biology Technology:
(Date:11/29/2016)... Lithuania , Nov. 29, 2016 /PRNewswire/ ... biometric identification and object recognition technologies, today ... (SDK) for fingerprint recognition solutions that run ... a fingerprint template using less than 128KB ... in compact devices that have limited on-board ...
(Date:11/22/2016)... India , November 22, 2016 According to ... (Fingerprint, IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and ... 2022", published by MarketsandMarkets, the market is expected to grow from USD ... a CAGR of 16.79% between 2016 and 2022. ... ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is ... analysis for Private Biobanks shows the highest Compounded Annual Growth ... region during the analysis period 2014-2020. ... CAGR of 9.95% followed by Europe ...
Breaking Biology News(10 mins):